600results about "Recombinant DNA-technology" patented technology

An improved method of treating cancers with engineered T cells is described.

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.

The present invention belongs to the field of plant genetics research, and particularly relates to gene functions for increasing plant biomass and seed yield. The present invention discloses the use of a gene that negatively regulates plant biomass and seed yield. This gene is the AT3G28990 gene whose nucleotide sequence is shown in SEQ ID NO: 1. By knocking out the AT3G28990 gene in plants, the biomass and seed yield of plants can be increased. Knocking out the AT3G28990 gene of Arabidopsis thaliana can effectively increase the biomass and yield of plants. This has important reference significance for the breeding of high-yield crops.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and / or therapeutic agent.

The technology described herein is directed to methods of generating CD4+CD8- single-positive T cells from CD4+CD8+ double positive T progenitor cells using differentiation in the presence of interleukin-7 (IL-7) and an anti-CD3 agent and in absence of Notch ligand and an anti-CD28 agent. Also described herein are CD4+CD8- single-positive T cells made by the methods described herein, which can be used for therapeutic applications.

To provide a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs.SOLUTION: A composition comprises rhGAA, wherein: 40% to 60% of N-glycan on the rhGAA are complex-type N-glycans; and each rhGAA molecule contains at least one bis-phosphorylated mannose-6-phosphate (bis-M6 P) glycan. A pharmaceutical composition comprising the composition and at least one pharmaceutically acceptable carrier or additive are also provided.SELECTED DRAWING: Figure 1A

This invention provides a system and method for capturing and detecting polynucleotide chains. [Solution] The method may include the step of labeling at least one subsequence within a polynucleotide chain to obtain a labeled polynucleotide chain having at least one label. The method may further include the step of supplying a polymer to the surface of a channel and causing the polymer to physically interact with the surface of the channel. The method may further include the step of supplying a sample containing a labeled polynucleotide chain to the channel, the step of applying an electric field to the labeled polynucleotide chain to promote a physical interaction between the labeled polynucleotide chain and the polymer on the surface of the channel and to capture the labeled polynucleotide chain on the surface of the channel, and the step of detecting at least one label within the labeled polynucleotide chain.

To provide a method, system, composition, and reagent kit for the diagnosis and differential diagnosis of Alzheimer's disease based on spatial transcriptomics in the human brain hippocampus, which enables differential diagnosis of Alzheimer's disease by detecting one or more of CCK, Neurogranin, and PMP2 carried by plasma-derived extracellular vesicles (EVs). [Solution] This nanoflow cytometry technology focuses on the clinical and research challenges of early and differential diagnosis of cognitive impairments associated with Alzheimer's disease (AD). By utilizing world-leading spatial transcriptomics and single-cell sequencing, along with novel nanoflow cytometry technology, it enables highly sensitive and high-throughput detection of central nervous system-derived EVs (EVs) present in peripheral blood. Offering the advantages of rapid and low-cost detection, and utilizing resources derived from Chinese brains, newly discovered central nervous system brain regions, and cell-specific EV markers, it enables rapid and highly efficient early and differential diagnosis of AD-related cognitive impairments, providing new technological means and methods for precise diagnostic work related to the clinical application and large-scale screening of AD cognitive impairments in clinical settings.

It is revealed that an organ such as pancreas can be regenerated by utilizing a fact that the deficiency of an organ is complemented by injecting an induced pluripotent stem cell (iPS cell) into a developed blastocyst in a blastocyst complementation method. Thus, the present invention has solved the above-described object. This provides a method for producing a target organ, using an iPS cell, in a living body of a non-human mammal having an abnormality associated with a lack of development of the target organ in a development stage, the target organ produced being derived from a different individual mammal that is an individual different from the non-human mammal.

The present application relates to a peptide having skin condition-improving activity and its uses, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a cosmetic composition for improving skin condition that contains the peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Provided are: a genome-edited plant production method by which genome editing can be applied to plants including the family Leguminosae that is difficult to transform, without undergoing processes of tissue culture requiring transformation and time; and a genome-edited plant obtained by said method. The present invention pertains to a genome-edited plant production method and a genome-edited plant obtained by said method, the genome-edited plant production method comprising: providing a cutout in a part of a plant capable of autonomously growing; injecting, to the cutout, an Agrobacterium-containing solution for genome editing; introducing a mutation into the plant without leaving a foreign gene therein; and collecting seeds from the plant, into which the mutation has been introduced, without subjecting the plant to a re-differentiation step, to obtain a genome-edited plant.

The present invention provides a method for producing immobilized cells for producing mannose, and a method for producing mannose, which include the steps of obtaining fermentation liquids of Escherichia coli or Bacillus subtilis in which α-glucan phosphorylase, phosphoglucomutase, glucose phosphate isomerase, mannose 6-phosphate isomerase, and mannose 6-phosphate phosphatase have been expressed by fermentation, and mixing the fermentation liquids to obtain a fermentation mixture.

The present invention provides a method and composition for generating basal forebrain cholinergic neurons (BFCNs). [Solution] A highly reproducible protocol for efficiently obtaining BFCNs from pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), provides a method and composition for generating BFCNs from stem cells, particularly BFCNs in which electrophysiological abnormalities associated with one or more mutations in PSEN2 have been repaired, as well as the use of such BFCNs in cell-based therapies for treating Alzheimer's disease. TIFF2026108846000021.tif41148

To provide a method for suppressing non-specific nucleic acid amplification in an RT-RamDA reaction.SOLUTION: The present invention provides a method for suppressing non-specific nucleic acid amplification that may occur in an RT-RamDA reaction solution by coexisting a template RNA and a chaotropic agent in the RT-RamDA reaction solution. Preferably, the final concentration of the chaotropic agent in the RT-RamDA reaction solution is more than 0 mM and 50 mM or less. The chaotropic agent is preferably at least one selected from the group consisting of guanidinium ion, urea ion, iodide ion, lithium ion, and salts thereof.SELECTED DRAWING: None

Systems and techniques are provided for making genetically engineered ion channels (ICs) with bioluminescent resonance energy transfer (BRET) complexes and using such ICs for efficient readout of neural activity and output of biological neuronal networks.SOLUTION: In one implementation, the disclosed technology includes identifying a target location in the IC for expression of a target protein including a donor tag protein and an acceptor tag protein, and modifying the genome of the neuronal cell at a portion associated with the target location in the IC. The technique further includes causing the neuronal cell to express the target protein in the IC according to the modified genome. In the first (second) state of the IC, the donor tag protein is at a first (second) distance from the acceptor tag protein that is related to the absence (presence) of energy transfer between the donor tag protein and the acceptor tag protein.SELECTED DRAWING: Figure 3A-3C

The present disclosure is directed to novel monoclonal antibodies that bind to ELTD1 and methods of use thereof, including the detection and treatment of cancer, multiple sclerosis, retinopathy, or promoting tissue regeneration.

To provide Monascus pilosus, a composition for weight loss and improvement of gut microbiota composition, and uses of the Monascus pilosus.SOLUTION: The main purpose of the present invention is to provide Monascus pilosus and a composition for weight loss and improvement of gut microbiota composition, wherein the composition comprises Monascus pilosus and / or a fermented product thereof, or comprises a functional ingredient comprising the fermented product thereof. Another objective of the present invention is to provide uses of Monascus pilosus in the manufacture of a composition for weight loss and improvement of gut microbiota composition. The composition of the present invention has the ability to reduce body weight and the ability to improve gut microbiota composition, for example, to reduce a ratio of Firmicutes to Bacteroidetes.SELECTED DRAWING: Figure 1

The present invention relates to modified amino acid degrons (MAADs) and methods for identifying factors that mediate the selective degradation of MAAD-tagged proteins.

The purpose of the present invention is to provide a novel technique for preventing muscle atrophy by inhibiting muscle degradation or directly promoting muscle synthesis without involving physical activity.　Provided is a muscle atrophy prevention agent containing, as an active ingredient, lactic acid bacteria having a muscle synthesis promotion effect and / or a muscle degradation inhibition effect, a processed product of the lactic acid bacteria, or an extract thereof. A lactic acid bacterium having the muscle synthesis promotion effect is Lactobacillus gasseri or the like, and a lactic acid bacterium having the muscle degradation inhibition effect is Lactobacillus reuteri or the like.

Provided is the use of a genetically engineered phage expressing a first peptide targeting a Programmed Cell Death protein 1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) and a second peptide targeting a cancer-related antigen for enhanced efficacy in cancer treatment. Thus, provided are methods for improved anti-cancer therapy, especially in the treatment of solid tumors, by using a recombinant phage that is capable of specifically targeting the PD-1 / PD-L1 pathway and specifically targeting a cancer antigen, as well as compositions and kits useful for such treatment methods.

The present invention has an object to provide a simpler and quicker method for diagnosing tinea, method for detecting a Trichophyton, or method for detecting the Trichophyton gene. Use of at least four kinds of specific primers each designed based on a DNA sequence of the Trichophyton gene makes it possible to simply and quickly detect the Trichophyton gene.

The present invention provides a new site for transplantation. Specifically, the present invention relates to a method for transplanting cells or tissues, particularly pancreatic islets, into the sub-rectus sheath site. The present invention also relates to a method for treating diabetes by transplanting pancreatic islets, particularly hPSC pancreatic islets, into a sub-rectus sheath position.

It provides a vaccine platform that can be tailored to target any tumor type and appropriately stimulates the expansion of specific anti-tumor immune cells. [Solution] Provided are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to a biotinylated component (e.g., a tumor cell, a tumor antigen, a virus, or a viral antigen). The self-assembling pharmaceutical compositions can further comprise an immunotherapy (e.g., an anti-PD-1 antibody). Also provided are methods of using these pharmaceutical compositions for preventing and / or treating cancer or inducing an immune response. Also provided are methods of using the self-assembling pharmaceutical compositions in combination with immunotherapy (e.g., an anti-PD-1 antibody).

The present invention relates to a low-serum medium composition for culturing Vero cells, and a method for culturing Vero cells and a method for producing a virus, both using the same.

Methods for generating multipotent radial glia-like cells and astrocyte-like cells from human pluripotent stem cells are provided, along with related compositions.

Provided herein is a composition and method for determining the quality of nucleic acid in a sample, comprising a first primer set and a second primer set.Further provided herein is a composition and method for determining the quality of nucleic acid in a sample, comprising a primer set for amplifying repetitive nucleic acid sequences.The present invention generally relates to determining the quality of nucleic acid in a sample, and more particularly relates to determining the quality of nucleic acid before library preparation and sequencing.

To provide methods and compositions for converting one cell type to another cell type.SOLUTION: A method for determining transcription factors required for conversion of a source cell to a cell exhibiting at least one characteristic of a target cell type comprises the steps of: determining differential expression of genes in the source and target cell types; determining a network score for each transcription factor (TF) in each of the source and target cell types based on the differential gene expression over at least one network, where the network contains information on interactions that affect gene expression; ranking the TFs based on an informational combination of the differential gene expression and the network scores, thereby identifying the set of transcription factors for the conversion from the source cell to the cell exhibiting the at least one characteristic of the target cell type.SELECTED DRAWING: None

To provide a method for prediction of response of a subject having a neuroendocrine tumor (NET) to peptide receptor radionuclide therapy (PRRT) treatment.SOLUTION: The method comprises: determining the expression level of each of at least 12 biomarkers including ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, NAP1L1, NOL3, TECPR2 and ALG9.SELECTED DRAWING: Figure 1

Systems and methods for identifying a diagnosis of a cancerous state for a somatic tumor specimen of a subject are provided.SOLUTION: The method receives sequencing information comprising an analysis of a plurality of nucleic acids from a somatic tumor specimen. The method identifies a plurality of features from the sequencing information including two or more of RNA, DNA, RNA splicing, viral, and copy number features. The method provides a first subset of features and a second subset of features from the identified plurality of features as input to a first classifier and a second classifier, respectively. The method generates two or more predictions of cancer status based at least in part on the identified plurality of features from the two or more classifiers. The method combines the two or more predictions with a final classifier to identify a diagnosis of cancer status for the subject's somatic tumor specimen.SELECTED DRAWING: Figure 1

This article discloses a method for selecting allogeneic T cell lines for therapeutic administration to patients who carry / have or are suspected of carrying / having the pathogen or cancer. It also discloses a method for selecting donors from which allogeneic T cell lines for therapeutic administration to patients who carry / have or are suspected of carrying / having the pathogen or cancer.